Amrutanjan Health Care
stock is worth watching as the stock is forming a 18-week, 19% deep Consolidation
Base. The current price is only 2.0% away from its ideal buy price of INR 805. Aggressive investors could use any tight area breakout inside the base as an opportunity to initiate a small position. A conservative approach may be to add the stock to your watchlist so that you are ready to pounce if it breaks out to the traditional entry point.
The key trend lines, 10 and 40-week moving averages are at a comfortable position. The current trends of both the averages are upward and the 10-week moving average is trending above the 40-week moving average. The current price of the stock is trading around 10.59% away from the 10-week moving average.
In the last twelve months, Amrutanjan Health Care
has rallied nearly 63.2% as compared to 52.6% for the Nifty500. It has a Relative Strength Rating
of 59. We definitely would like to see improvement in the rating. At this point we are taking a step back and focusing on the RS Line.
The RS Line remains in a downtrend for the last four weeks. However, this is not unusual for a leading stock as the stock sets up base for its next leg up or at the very beginning of a new trend. At this point, the overall long term trend of the line is upward. If Amrutanjan Health Care
can maintain a healthy upward move, it could make sense as a CANSLIM
trade. Amrutanjan Health Care
stock has strong institutional support. The Accumulation/Distribution Rating
of 'B' represents heavy institutional buying over the past 13 weeks. Although the shares held by institutions dropped in the last quarter, the number of institutions holding the stock increased at the same time. This shows increasing interest among the institutions.
On the earnings front, Amrutanjan Health Care
has an excellent EPS Rank of 88, which indicates consistency in earnings. The earnings and sales for the stock have grown by 102% and 18%, respectively over the past three years. Its 3-years earnings stability is 26, on a 0 to 99 scale (lower the better). Over the past five years, the earnings and sales for the stock have grown by 30% and 14%, respectively. The 5-years earnings stability is 59. The return on equity for the last reported year is 33%.
The stock belongs to the industry group of Medical-Generic Drugs. You would still want to see some improvement in the industry group rank for the group. The current industry group rank is 112. The current price of Amrutanjan Health Care
is -2% off from its 52-week high price and 97% above its 52-week low price.
The stock appears on our idea lists: Minervini Trend Template.
What do you think? Please email us any questions or comments.Disclaimer: Information contained herein is not and should not be construed as an offer, solicitation, or recommendation to buy or sell securities. It is for educational purposes only.For more information, see our Legal disclosures here.